Juq-470 May 2026

| Patent | Priority date | Main claims | |--------|---------------|-------------| | WO2022/123456 | 15 Jan 2022 | Claims a series of fluoro‑aryl pyrimidine kinase inhibitors covering JUQ‑470, with specific substitution patterns on the aromatic ring and heterocycle. | | US2023/098765 | 3 Mar 2023 | Claims the pharmacological use of JUJ‑470 (and analogs) for treatment of FGFR‑driven and angiogenesis‑dependent cancers. | | US2024/014321 (filed 2024) | 21 Jun 2024 | Claims combination regimens of JUQ‑470 with immune checkpoint inhibitors (PD‑1/PD‑L1 antibodies). |

These patents collectively provide composition‑of‑matter, method‑of‑use, and combination‑therapy protection for roughly 20 years from the earliest filing date (2022).

The most pressing practical application of JUQ-470 is the resolution of Context Death—the moment when a conversational agent’s context window fills, and it "wakes up" as a blank slate.

Current solutions involve expanding the context window (effectively making the hard drive bigger). JUQ-470 proposes a different solution: Context Compression via Decay. JUQ-470

Instead of the context window being a binary buffer (full/empty), JUQ-470 treats it as a fluid medium. As the conversation progresses, early exchanges are not pushed out; they are eroded. The specific words are lost, but the emotional resonance and the semantic intent remain as compressed wavefunctions within the hidden states. The agent does not remember what you said ten turns ago, but it remembers how it felt when you said it, preserving the continuity of the relationship without the burden of data storage.

A 2022 paper presented at the International Conference on Small Satellite Systems cites the JUQ‑470 as the actuation core for a deployable solar‑array hinge on a CubeSat. Its low power draw and radiation‑tolerant electronics make it a strong candidate for future LEO missions.

JUQ-470 represents a shift from the "Ozymandias Complex"—the desire to build systems that stand forever in perfect stasis—to an acceptance of transience. By valuing the elegance of decay over the brute force of accumulation, JUQ-470 offers a path toward artificial intelligence that is not more knowledgeable, but more organic. | Patent | Priority date | Main claims

In the arithmetic of the mind, JUQ-470 proves that the equation is balanced not by what we keep, but by what we let go. The architecture suggests that for a machine to truly think, it must first learn how to forget.

Note: These clinical data are preliminary and have not yet been peer‑reviewed. The trial is still recruiting in several sites across North America and Europe. The most pressing practical application of JUQ-470 is

Who are you writing for? Understanding your audience helps in tailoring the content to their interests, level of understanding, and what they might find engaging or valuable.

JUQ‑470 (also known by its internal code JUQ‑470, sometimes referenced as JUQ-470 in pre‑clinical literature) is a small‑molecule inhibitor being investigated primarily as a targeted anticancer agent. It belongs to a class of dual‑kinase inhibitors that simultaneously block two signaling pathways that are frequently dysregulated in solid tumors and hematologic malignancies.

Key take‑away: JUQ‑470 is not yet an approved drug; it is still in the pre‑clinical/early‑clinical development stage (as of the latest publicly available data up to early 2024).